These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 31810998

  • 21. European Real-World Assessment of the Clinical Validity of a CE-IVD Panel for Ultra-Fast Next-Generation Sequencing in Solid Tumors.
    Normanno N, Machado JC, Pescarmona E, Buglioni S, Navarro L, Esposito Abate R, Ferro A, Mensink R, Lambiase M, Lespinet-Fabre V, Calgua B, Jermann PM, Ilié M, Hofman P.
    Int J Mol Sci; 2023 Sep 07; 24(18):. PubMed ID: 37762091
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.
    Supplee JG, Milan MSD, Lim LP, Potts KT, Sholl LM, Oxnard GR, Paweletz CP.
    Lung Cancer; 2019 Aug 07; 134():96-99. PubMed ID: 31320002
    [Abstract] [Full Text] [Related]

  • 24. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia.
    Atak ZK, Gianfelici V, Hulselmans G, De Keersmaecker K, Devasia AG, Geerdens E, Mentens N, Chiaretti S, Durinck K, Uyttebroeck A, Vandenberghe P, Wlodarska I, Cloos J, Foà R, Speleman F, Cools J, Aerts S.
    PLoS Genet; 2013 Aug 07; 9(12):e1003997. PubMed ID: 24367274
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Clinical Next-Generation Sequencing Pipeline Outperforms a Combined Approach Using Sanger Sequencing and Multiplex Ligation-Dependent Probe Amplification in Targeted Gene Panel Analysis.
    Schenkel LC, Kerkhof J, Stuart A, Reilly J, Eng B, Woodside C, Levstik A, Howlett CJ, Rupar AC, Knoll JHM, Ainsworth P, Waye JS, Sadikovic B.
    J Mol Diagn; 2016 Sep 07; 18(5):657-667. PubMed ID: 27376475
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples.
    Williams HL, Walsh K, Diamond A, Oniscu A, Deans ZC.
    Virchows Arch; 2018 Oct 07; 473(4):489-503. PubMed ID: 30105577
    [Abstract] [Full Text] [Related]

  • 29. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC.
    Liu SY, Gou LY, Li AN, Lou NN, Gao HF, Su J, Yang JJ, Zhang XC, Shao Y, Dong ZY, Zhou Q, Zhong WZ, Wu YL.
    J Thorac Oncol; 2016 Sep 07; 11(9):1503-10. PubMed ID: 27257131
    [Abstract] [Full Text] [Related]

  • 30. Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.
    Park K, Tran H, Eng KW, Ramazanoglu S, Marrero Rolon RM, Scognamiglio T, Borczuk A, Mosquera JM, Pan Q, Sboner A, Rubin MA, Elemento O, Rennert H, Fernandes H, Song W.
    Arch Pathol Lab Med; 2020 Dec 01; 144(12):1535-1546. PubMed ID: 32045275
    [Abstract] [Full Text] [Related]

  • 31. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.
    Hou H, Yang X, Zhang J, Zhang Z, Xu X, Zhang X, Zhang C, Liu D, Yan W, Zhou N, Zhu H, Qian Z, Li Z, Zhang X.
    Sci Rep; 2017 Nov 06; 7(1):14605. PubMed ID: 29097733
    [Abstract] [Full Text] [Related]

  • 32. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
    Gray PN, Vuong H, Tsai P, Lu HM, Mu W, Hsuan V, Hoo J, Shah S, Uyeda L, Fox S, Patel H, Janicek M, Brown S, Dobrea L, Wagman L, Plimack E, Mehra R, Golemis EA, Bilusic M, Zibelman M, Elliott A.
    Oncotarget; 2016 Oct 18; 7(42):68206-68228. PubMed ID: 27626691
    [Abstract] [Full Text] [Related]

  • 33. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
    Mas A, Alonso R, Garrido-Gómez T, Escorcia P, Montero B, Jiménez-Almazán J, Martín J, Pellicer N, Monleón J, Simón C.
    Am J Obstet Gynecol; 2019 Oct 18; 221(4):320.e1-320.e23. PubMed ID: 31121144
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
    Tong JH, Yeung SF, Chan AW, Chung LY, Chau SL, Lung RW, Tong CY, Chow C, Tin EK, Yu YH, Li H, Pan Y, Chak WP, Ng CS, Mok TS, To KF.
    Clin Cancer Res; 2016 Jun 15; 22(12):3048-56. PubMed ID: 26847053
    [Abstract] [Full Text] [Related]

  • 38. SNVSniffer: an integrated caller for germline and somatic single-nucleotide and indel mutations.
    Liu Y, Loewer M, Aluru S, Schmidt B.
    BMC Syst Biol; 2016 Aug 01; 10 Suppl 2(Suppl 2):47. PubMed ID: 27489955
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Targeted RNA Sequencing in Non-Small Cell Lung Cancer.
    Ritterhouse LL.
    J Mol Diagn; 2019 Mar 01; 21(2):183-185. PubMed ID: 30664939
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.